Open Access<p>Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases</p>
Author(s) -
Lijun Du,
Lei Zhang,
Ling Li,
Xin Li,
Jiaqin Yan,
Xinhua Wang,
Xiaorui Fu,
Zhenchang Sun,
Xudong Zhang,
Zhaoming Li,
Jingjing Wu,
Hui Yu,
YuHsu Chang,
Zhiyuan Zhou,
Feifei Nan,
Xiaolong Wu,
Li Tian,
Mingzhi Zhang
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s262039
Subject(s) - medicine , thalidomide , etoposide , regimen , lymphoma , natural killer t cell , leukocytopenia , t cell lymphoma , gastroenterology , chemotherapy , oncology , immunology , t cell , immune system , multiple myeloma
Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTL) is a specific subtype of peripheral T cell lymphoma (PTCL) with a poor prognosis. To date, there exist no standard therapeutic regimens for relapsed/refractory (R/R) ENKTL. More potent treatment strategies are urgently needed to improve the survival of these patients with R/R ENKTL. Herein, we present three R/R ENKTL patients who failed prior therapies (L-asparaginase containing chemotherapy, radiotherapy or biological-cell therapy, etc.) benefited from the combination regimen comprised of anti-programmed-death-1 (PD-1) antibody toripalimab, chidamide, etoposide, and thalidomide. They received the treatment regimen continuously until the disease progression occurs. As of data collection, two patients achieved complete remission (CR) after 4, 6 cycles of treatment, respectively, and another patient was evaluated as partial remission (PR) after 2 cycles. Treatment-related adverse events (AEs) mainly presented grade 2~3 leukocytopenia and anemia, which were controllable. It follows that PD-1 antibody, chidamide, etoposide, and thalidomide (PCET) regimen may be a promising choice for patients with R/R ENKTL and warrants further investigation.